Results 1 to 10 of about 27,283 (265)

Momordica charantia-Derived Extracellular Vesicles Provide Antioxidant Protection in Ulcerative Colitis. [PDF]

Molecules, 2023
Plant-derived extracellular vesicles are functional nanovesicles that have significant applications in both disease prevention and treatment, as well as for use as drug carriers.
Wang F, Yuan M, Shao C, Ji N, Zhang H, Li C.   +5 more
europepmc   +2 more sources

Bioactives of Momordica charantia as Potential Anti-Diabetic/Hypoglycemic Agents

Molecules, 2022
Momordica charantia L., a member of the Curcubitaceae family, has traditionally been used as herbal medicine and as a vegetable. Functional ingredients of M. charantia play important roles in body health and human nutrition, which can be used directly or
Bilin Xu, Zhiliang Li, Ting Zeng, Jianfeng Zhan, Shuzhen Wang, Chi-Tang Ho, Shiming Li   +6 more
doaj   +2 more sources

Could Momordica Charantia Be Effective In The Treatment of COVID19?

Cumhuriyet Science Journal, 2022
One of the deadliest diseases is the SARS-CoV-2 virus, today. The rate of spread of this virus is very high. Momordica Charantia extracts studied for this virus.
Burak Tüzün, Koray Sayin, Hilmi Ataseven   +2 more
doaj   +2 more sources

Crossability studies among Momordica charantia var. charantia and Momordica charantia var. muricata

The Indian Journal of Agricultural Sciences, 2019
Inter and intra-specific hybridization is a powerful breeding method for crop improvement and it has potential to broaden the genetic base of the cultivated species. M. charantia var.
VIJAYAKUMAR RATHOD, TUSAR KANTI BEHERA, ANILABH DAS MUNSHI, VINOD VINOD, GOGRAJ SINGH JAT   +4 more
doaj   +3 more sources

Momordica charantia L.-derived exosome-like nanovesicles stabilize p62 expression to ameliorate doxorubicin cardiotoxicity. [PDF]

J Nanobiotechnology
Doxorubicin (DOX) is a first-line chemotherapeutic drug for various malignancies that causes cardiotoxicity. Plant-derived exosome-like nanovesicles (P-ELNs) are growing as novel therapeutic agents.
Ye C, Yan C, Bian SJ, Li XR, Li Y, Wang KX, Zhu YH, Wang L, Wang YC, Wang YY, Li TS, Qi SH, Luo L.   +12 more
europepmc   +2 more sources

Momordica charantia for type 2 diabetes mellitus. [PDF]

Cochrane Database of Systematic Reviews, 2012
Momordica charantia (bitter gourd) is not only a nutritious vegetable but it is also used in traditional medical practices to treat type 2 diabetes mellitus. Experimental studies with animals and humans suggested that the vegetable has a possible role in
Cheow, Peng Ooi, Tengku Abdul Hamid, Tengku Aizan, Yassin, Zaitun   +2 more
core   +5 more sources

Comparative evaluation of antibacterial efficacy of chlorhexidine mouthwash and Momordica charantia, Spinacia oleracea mouthwash against Streptococcus mutans, Lactobacillus spp., and Porphyromonas gingivalis − An in vitro study

Journal of Orofacial Sciences, 2023
Introduction: Various advances have been made in pharmacology and synthetic organic chemistry, the dependency on natural products, particularly on herbs, remains relatively unchanged.
Krishna S Kadam, Niraj S Gokhale, Shivayogi M Hugar, Neha Kohli, Suneel Dodamani, Shivani Tendulkar   +5 more
doaj   +1 more source

Therapeutic Effect of Momordica charantia on Blood Glucose, Lipid Profile and Oxidative Stress in Type 2 Diabetes Mellitus Patients: A Randomised Controlled Trial [PDF]

Journal of Clinical and Diagnostic Research, 2018
Introduction: Momordica charantia (Bitter Melon) is known to have anti-diabetic property. Animal studies have documented its hypoglycaemic and lipid lowering effect.
Suchitra Kumari, Ipsita Dash, Kishore Kumar Behera   +2 more
doaj   +1 more source

Recent progress in research on Momordica charantia polysaccharides: extraction, purification, structural characteristics and bioactivities

Chemical and Biological Technologies in Agriculture, 2023
Momordica charantia ( M. charantia ), as a common edible vegetable and herb, is mainly distributed in tropical and subtropical regions of the world. M. charantia polysaccharides (MCPs), as the main pharmacologically active component in M. charantia , are
Kai Zhan, Xiaolong Ji, Lei Luo
semanticscholar   +1 more source

In silico study of the active compounds in bitter melon (Momordica charantia L) as antidiabetic medication [PDF]

Pharmaciana, 2018
Antidiabetic are many drugs available in the market, but most medications have side effects that are relatively high and cause toxicity, so it needs tobe develoved search of new drug compounds were more potent drugs with side effects as low.
Ruswanto Ruswanto, Richa Mardianingrum, Tresna Lestari, Tita Nofianti, Lilis Tuslinah, Dudi Nurmalik   +5 more
doaj   +1 more source